Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

2020564 citationsJournal Articlebronze Open Access

Authors

Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment.

Good health and well-being

Published in: British Journal of Dermatology

Volume 184, Issue 3, pp. 437-449

Field-Weighted Citation Impact: 42.95